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esponsibility of InstAbstract Spurred by signiﬁcant progress in materials chemistry and drug delivery, charge-reversal
nanocarriers are being developed to deliver anticancer formulations in spatial-, temporal- and dosage-
controlled approaches. Charge-reversal nanoparticles can release their drug payload in response to speciﬁc
stimuli that alter the charge on their surface. They can elude clearance from the circulation and be
activated by protonation, enzymatic cleavage, or a molecular conformational change. In this review, we
discuss the physiological basis for, and recent advances in the design of charge-reversal nanoparticles that
are able to control drug biodistribution in response to speciﬁc stimuli, endogenous factors (changes in pH,
redox gradients, or enzyme concentration) or exogenous factors (light or thermos-stimulation).
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Cancer is a leading cause of death around the world. According to the
mortality data from World Health Organization in 2015, there were an
estimated 84 million cancer deaths in the last decade1. Cancer
development has been deﬁned as a multistep process by which an
initiating event (e.g., environmental insult) leads to malignant prolif-
eration. As a small tumor mass forms, the surrounding healthy tissue is
unable to compete with the cancer cells for an adequate supply of
nutrients from the blood system, leading to apoptosis and necrosis of
the normal cells followed by dysfunction of primary organs and death2.
Current therapeutic strategies for most cancers involve a combination
of surgical resection, radiation therapy, and chemotherapy. However,
signiﬁcant morbidity and mortality are always associated with these
therapies due to their off-target effects on the “normal” cells. The
efﬁcacy of a chemotherapy regimen is directly correlated with the
ability to selectively target tumor tissue, overcome biological barriers,
and “smartly respond” to the tumor environment to release therapeutic
agents3. In conventional drug delivery, the drug is exposed directly to
serum without protection. The drug concentration in the blood
increases rapidly after administration and then declines. The purpose
of an ideal drug delivery system (DDS) is to adjust the drug
concentration within a desired therapeutic range after a single dose,
and carry the drug to a targeted region while simultaneously lowering
the systemic levels of the drug4. Charge-reversal nanoparticles exert
signiﬁcant potential for the speciﬁc targeting and release of anti-cancer
drugs. Nanoparticles are deﬁned as submicronic colloidal systems.
Nanosized drug carriers have a variety of intrinsic advantages over
conventional drug delivery systems, such as large payload capacity for
anticancer formulations, protection from degradation, multivalent
targeting moieties, and controlled or sustained release that reduces
adverse effects while enforcing the safety margin of the antitumor
agents5–7. Nanoparticles are usually taken up by various metabolic
systems depending on their surface characteristics. Generally, the
positive charge facilitates the binding of nanoparticles to the cell
membrane, leading to a signiﬁcant improvement in membrane transportFigure 1 Endogenous and exogenous stimuli-responsive charge-reversal
environment–triggered charge-reversal delivery; (C) tumor protease-trigge
drug delivery; and (E) thermo-responsive charge-reversal drug delivery.properties because of the intrinsic negative surface charge of the cell
membrane. However, this positive charge might also strengthen the
nonspeciﬁc binding of vectors to normal tissue8. The luminal surface of
blood vessels is well known to have a negatively charged surface
contributed by sulfated and carboxylate sugar moieties, meaning that
nanoparticles with high positive charges will bind nonspeciﬁcally to the
luminal surface of vascular walls and be rapidly cleared from the blood
circulation9. Charge-reversal nanoparticles combine the targeting
advantages of a conventional “smart” nanoparticle with a charge-
switch characteristic for drug release. Surface charge is designed to be
obscured during the blood circulation and uncovered at tumor sites.
Thus, these novel anti-cancer drug carriers have attracted tremendous
attention for delivery of anticancer agents. Herein, we provide a brief
review of several possible targeting delivery strategies for charge-
reversal nanoparticles.2. Endogenous stimuli-responsive charge-reversal delivery
2.1. pH-triggered charge-reversal delivery
Low cellular pH has been widely used to design sensitive drug
delivery strategies. Previous reports demonstrated that pH values vary
signiﬁcantly in different tissues or organs, (such as stomach and brain),
and in morbid states, (such as diabetes, infection, inﬂammation, and
tumor)10. The pH in tumor tissue is lower than that in normal tissues
because of the high rate of glycolysis in cancer cells. Compared with
the pH 7.4 of normal tissue, the pH in a tumor has been demonstrated
to range from 5.7 to 7.8. Additional pH differences are observed at the
subcellular level. The late endosomes and lysosomes have a much
lower pH, in the range of 4.5–5.5. Several drug carriers are absorbed
through endocytosis and assimilated within endosomes and lyso-
somes. This pH gradient is signiﬁcant for cancer drug delivery. pH-
Sensitive nano-systems are designed to stabilize the cargo at
physiological pH, and release the drug rapidly when the pH
triggering-point is reached (Fig. 1A). Kim et al.11 synthesized adelivery. (A) pH-triggered charge-reversal delivery; (B) tumor redox
red charge-reversal nanoparticles; (D) light-triggered charge-reversal
Charge-reversal nanoparticles 263poly(ethylene oxide)-b-poly(methacrylic acid) (PEO-b-PMA) copoly-
mer with doxorubicin (DOX) incorporated into the ionic cores of
PEO-b-PMA micelles via electrostatic interactions. DOX is positively
charged at physiological conditions. The ammonium group in the
daunosamine part of DOX and the hydrophobic interactions between
the anthracycline residues of DOX provide stabilization of the
complex. The protonation of a carboxylic group in the core of the
micelles leads to DOX release at lower pH. Up to 50% of the DOX
was released during the ﬁrst hour at pH 5.5. Yu and coworkers12
synthesized mPEG-PU(HEP-co-DMPA)-mPEG polyurethane triblock
copolymers (PS-PUs). The zeta potential showed a charge-reversal
point at about pH 5.7, 6.4, and 6.9 for PS-PU2, PS-PU3 and PS-PU4.
It suggested that the transition pH of PS-PUs was tunable by changing
the molar ratio of piperazine/carboxyl, where the tertiary amino groups
were protonated and generate an isoelectric point with carboxylic acid
groups at a speciﬁc pH. Wang and colleges13 demonstrated a stepwise
pH-responsive nanoparticle system containing charge reversible
pullulan-based (i.e., CAPL) shell and poly(β-amino ester) (PBAE)/
poly(lactic-co-glycolic acid) (PLGA) core. This nanoparticle system
was designed as a carrier of paclitaxel (PTX) and combretastatin A4
(CA4) for combining antiangiogenesis and chemotherapy to treat
hepatocellular carcinoma (HCC). CAPL-coated PBAE/PLGA (CAPL/
PBAE/PLGA) nanoparticles displayed a step-by-step response to
weakly acidic tumor microenvironment and endo/lysosome through
the cleavage of β-carboxylic amide bond in CAPL and the “proton-
sponge” effect of PBAE, thus achieving the efﬁcient and orderly
releases of CA4 and PTX.2.2. Tumor redox environment-triggered charge-reversal
delivery
During the process of intracellular oxygen metabolism, immune-
system attack on pathogens, as well as a number of human
pathological conditions, free radicals and reactive oxygen species
(ROS) present and harm the human internal environment. Multiple
mechanisms or processes exist to protect against free radicals and
ROS. However, these protective mechanisms may be overwhelmed or
inefﬁcient in handling free radicals/ROS, leading to “oxidative stress”.
The main protective mechanisms against ROS include superoxide
dismutase (SOD), catalase, glutathione (GSH), protein thiols, and
other intracellular redox couples14. These processes constitute a
complex intracellular network designed to maintain a slightly reducing
environment. Many researchers have utilized this cellular characteristic
for the targeted and charge-reversal delivery of anti-tumor drugs
(Fig. 1B). Caruso et al.15 employed a layer-by-layer technique to
construct a charge-reversal nanoparticle which can facilitate the
absorption of another layer of oppositely charged polyelectrolyte.
They constructed poly(N-vinylpyrrolidone) (PVPON) and poly
(methacrylic acid) (PMA) capsules. The disulﬁde linkages were much
more stable in a normal physiological environment, such as the
bloodstream, and were cleaved under reducing conditions such as the
cytoplasm of tumor cells. Shen and coworkers16 constructed a reactive
oxygen species labile charge-reversal polymer, poly[(2-acryloyl) ethyl
(p-boronic acid benzyl) diethylammonium bromide] (B-PDEAEA).
The polymer was strongly positively charged to which DNA could be
effectively trapped and compressed into nanoparticles. The polymer
tends to become negatively charged after triggering by intracellular
ROS. The quaternary ammonium compound released p-quinone
methide (p-hydroxylmethylenephenol, HMP) and leaving behind a
tertiary amine following oxidation of the boronic acid group by ROS.It subsequently auto-catalyzed fast hydrolysis of the ester group
producing poly(acrylic acid).
2.3. Tumor protease triggered charge-reversal nanoparticles
Mounting evidence supports the point that extracellular proteases,
such as the matrix metalloproteinases (MMPs), regulate many
biochemical factor changes in the microenvironment during tumor
progression17. These proteases mediate various physiological
processes and signaling pathways and thus they play a key role
in signal communication between tumor cells and the extracellular
environment (Fig. 1C).
Andresen et al.18 constructed a novel lipopeptide–poly(ethylene
glycol) (PEG) conjugate composed of a lipid-anchor, a peptide
sensitive to MMP2, and a PEG chain. The amphiphilic molecule
consists of dimyristeroyl (DM) conjugated to 2,3-diamino-propio-
nate (DAP), which is conjugated to the N-terminal of peptide
WIPVSLRSGEEEE, and then to PEG 2000 through its C-terminal.
After cleavage of the peptide by MMP2, the charge reverses from
negative to positive at lower pH. Katayama and co-workers19
constructed protein kinase (PK)-responsive nanoparticles (NPs)
comprising a hydrophobically modiﬁed peptide substrate for PKs
and a ﬂuorescein-labeled polyanion (pA-F). Initially, the ﬂuores-
cence of ﬂuorescein was largely quenched due to self-quenching
within lipopeptides and pA-F aggregates. However, PK-catalyzed
phosphorylation of cationic lipopeptides can reverse nanoparticle
charge and dissociate nanoparticles, as evidenced by the prominent
ﬂuorescence emission recovery.3. Exogenous stimuli-responsive charge-reversal delivery
3.1. Light-triggered charge-reversal drug delivery
Various physical and chemical stimuli as well as their combination
can switch the modiﬁed electrode interface of nanoparticles. There are
active and inactive states for electrochemical, electrocatalytic and bio-
electrocatalytic reactions. The electron transfer from these reactions
may be applied for charge-reversal drug delivery systems. Light, a
noninvasive approach, is a quite attractive trigger for delivering anti-
cancer agents capable of rapid and precise release. Since the 1980s,
photodynamic therapy has served as a promising treatment method
which involves the utilization of a photosensitizing agent coupled with
an appropriate light source. Although only a few methods have made
it to the clinic, many photo-sensitizing agents have been found in the
laboratory20. Light-responsive charge-reversal nanoparticles are used
as a microcarrier to deliver different drugs into cells21. A wide range
of research is currently under study to optimize the light-responsive
materials to achieve therapeutically efﬁcient and reproducible release
proﬁles.
Shea et al.22 synthesized charge-reversal spherical bridged
polysilsesquioxanexerogel (BPS) nanoparticles, which can be
triggered by UV irradiation. These featured negative colloidal
charges, which are intrinsic to the BPS nanoparticles. Secondary
amine groups emerged in the bridging moieties, reversing the
nanoparticle charge from negative to positive. It was previously
reported that organically derivatized gold nanoparticles functio-
nalized with a photoresponsive linker (thioundecyl-tetraethyle-
neglycolester-o-nitrobenzy-lethyldimethyl ammonium bromide,
TUNA) were positively charged with an average particle dia-
meter of 5 nm in PBS (pH¼7.4). The photolabile linker was
cleaved with photoirradiation at 356 nm, resulting in the
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charge repulsion unveiled the mesopores leading to the release of
guest molecules23. Rotello et al.24 constructed a positively
charged gold nanoparticle joined to a photoactive o-nitrobenzyl
ester linkage. It could be triggered by light, which allowed a
temporal and spatial release of DNA. Near-UV irradiation
cleaved the nitrobenzyl linkage, releasing the positively charged
alkyl amine and leaving behind a negatively charged carboxylate
group. The charge-reversal repulsed DNA from the nanoparticle
effectively, resulting a high level of recovery of DNA transcrip-
tion in vitro and in vivo.
3.2. Thermo-responsive charge-reversal drug delivery
Thermo-responsive drug delivery is among the most investigated
stimuli-responsive strategies. Thermo-responsiveness has been widely
explored in oncology. Thermo-responsive charge-reversal carriers
retain their load at body temperature and reverse their surface charge
following thermos-response triggering. Caruso et al.25 synthesized a
poly(allylamine) hydrochloride (PAH) coated SiO2 nanoparticle. The
act of heating could cause the cationic polymer PAH to lose its
inherent positive charge and become negative without any polymer
desorption. The results of the fouling properties and cell-association
behavior of the particles showed that heating reduced the protein
fouling and cell association of PAH thin ﬁlms and particles. Richtering
and coworkers26 constructed magnetic nanoparticles (MNP)-coated
carriers, MG/PDADMAC/PSS/MNP (microgels/poly(diallyldimethy-
lammonium chloride)/poly(sodium 4-styrenesulfonate)/magnetic nano-
particles), using layer-by-layer methods. A layer of negatively charged
PSS covered the positively charged MNP. MNP was able to generate
enough heat to raise the temperature and lead to the collapse of each
layer following the charge-reversal from negative to positive.4. Application of charge-reversal systems in cancer
treatment
4.1. Chemotherapeutics delivery
A number of anticancer drugs, such as anthracylines, camptothecin
and cisplatin, are DNA-toxins. They exert their power through
targeting nuclear DNA resulting in DNA damage, or by inhibiting
topoisomerase involved in DNA replication to induce cell death
(apoptosis)27,28. They have to enter the nucleus to elicit their
pharmacological responses. However, drug-resistant tumor cells
limit the access of cytosolic drugs to the nucleus. P-glycoprotein is
overexpressed on the membranes of cytoplasmic organelles and
the nuclear envelope in drug-resistant cells. P-glycoprotein acti-
vates the intracellular drug sequestration and outwards transport of
drugs from their intracellular targets29.
Charge-reversal nanoparticles switch the negatively charged
surface to positively charged surface for the enhanced cellular
uptake due to the enhanced nanoparticle-cellular membrane
interaction30–32. Wang and colleagues33 developed a kind of
charge-reversal nanoparticles based on zwitterionic polymer by
introducing a tumor extracellular acidity-sensitive group as the
anionic part of the Zwitterionic polymer. The block copolymer of
poly(ε-caprolactone) (PCL) and poly(allyl ethylene phosphate)
(PCL-b-PAEP) was well established by controlled ring-opening
polymerization. The amphiphilic Zwitterionic block copolymer
PCL-b-(PAEP-g-TMA/DMA) self-assembled and encapsulated
DOX. The Zwitterionic polymer diminished its anionic part,forming PCL-b-(PAEP-g-TMA/Cya) in response to the lower
pH. The formed nanoparticles can switch from negative charge
to positive charge and become recognizable by tumor cells. Zhang
and coworkers34 developed methoxy poly(ethylene glycol)-b-poly
(ε-caprolactone-co-γ-dimethyl maleamidic acid-ε-caprolactone)
[mPEG-b-(PCL-co-DCL)] for the pH-tailored charge-reversal of
intracellular delivery of DOX. The β-carboxylic amide-
functionalized polymer micelles are negatively charged and
regarded stable in neutral solution. They quickly turn positive at
pH 6.0 due to the hydrolysis of β-carboxylic amides in acidic
conditions. The MTT results implied that mPEG-b-(PCL-co-DCL)
micelles were biocompatible with HepG2 cells while DOX-loaded
micelles showed signiﬁcant cytotoxicity. Xing et al.35 constructed
a charge-reversal graphene oxide (GO) for the controlled release of
anticancer drugs, such as DOX. Citraconic anhydride-
functionalized PAH (PAH-Cit) is a charge-reversal polyelectrolyte,
which can convert to poly(allylamine) in the acidic environments,
such as endosomes and lysosomes. They developed a GO-based
charge-reversal nanocarrier (GO-Abs/PEI/PAH-Cit/Dox) for the
enhanced delivery into U87 MG tumor-bearing nude mice.
Treatment of this DOX-loaded nanoparticle for 12 h showed
strong ﬂuorescence, suggesting an effective DOX delivery by this
GO particle.4.2. Gene delivery
Gene therapy has received tremendous attention due to its potential
application for delivering missing genes or functional substitutes
of defective genes. Effective gene-delivery vectors hold a vital role
in the success of gene therapy. These vectors could transport
plasmid DNA, small interfering RNA, or antisense oligonucleo-
tides into target cells. Viral and synthetic vectors are the two most
common methods for gene delivery. Gene-delivery via viral
approach is conventional and efﬁcient.
Compared with virus vectors, there are intense studies on
nonviral vectors for their low toxicity, high loading capacity,
nonimmunogenicity, and ease of synthesis. Yet, limitations, such
as low transfection efﬁciencies and inactivation in the presence of
serum, restrict the wide application of nonviral vectors. To
overcome these limitations, charge-reversal strategies, such as
modifying the amphile structure and adding an alternative cationic
head group, have been used for the efﬁcient delivery of genes.
Poly(L-lysine) (PLL)- and polyethylenimine (PEI)-based gene
carriers have been widely used as non-viral gene carriers36. They
can promote the entry of carriers into the nucleus37. Drug and
cationic polymer conjugates might be delivered into the nucleus.
However, the cationic nanoparticles have strong non-speciﬁc
cellular uptake in the bloodstream that could lead to severe serum
inhibition following rapid clearance from the plasma compartment,
which limits their function as drug carriers in vivo38. So an ideal
delivery strategy might be masking the positive charge during
blood circulation, but reversing it upon arrival at the tumor site.
The charge-reversal nanoparticle mainly performs two roles:
ﬁrst, it releases the genes after delivering them to the tumor site;
second, it destabilizes the bilayer and reverses surface charges
upon stimulation by the tumor microenvironment or manual
intervention (near infrared light, thermo). Liang and coworkers39
developed a nanocarrier system coated with chitosan and a pH-
responsive charge-reversible polymer, PAH-Cit, to deliver siRNA.
The citraconic amide side chains of the anionic charge-shifting
polymer, PAH-Cit, were hydrolyzed under lower pH conditions
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structure of the nanoparticles and thus repelled the PEI/siRNA.
The amino groups on PAH contributed to the “proton-sponge”
effect to facilitate the release of siRNA. This overcame the strong
binding between Au nanoparticles and siRNA. Pfeifer et al.40
synthesized well-deﬁned cationic polylactides (CPLAs) with
tertiary amine groups using thiol-ene click functionalization of
an allyl-functionalized polylactide to yield polymers with tunable
charge densities. Kempson and coworkers41 developed branched
polyethylenimine (bPEI) and copolymers, consisting of PEG,
histidine (His), and glutamic acid (Glu). The bPEI25K/siRNA/
poly (PEG-His-PEG-Glu) had a hydrodynamic size of 150 nm and
negative ζ-potential (10.5 mV). Flow cytometry results showed
an increased ﬂuorescence intensity in a step-wise manner depend-
ing on pH to release siRNA.4.3. Protein delivery
In the last decade, pharmaceutically active peptides and proteins
have been invented with the progress in biotechnological techni-
ques and genetic engineering. However, the application of these
novel therapeutic biomolecules are limited by their large size, short
plasma half-life, high elimination rate (easy to be deteriorated by
enzyme and body ﬂuids), inability to pass through the cell
membranes, and poor oral bioavailability. This leads to the
frequent injection of drug over a long treatment period when such
biomolecules are used clinically42. The traditional administration
methods for protein drugs are oral and parenteral administration.
Degrading factors (e.g., water and enzymes) limit the effectiveness
of these approaches.
Entrapment of these drugs into a particular carrier offers an
effective approach to overcome these problems. The strategy of
delivering proteins to biological compartments by nanoparticle is a
promising technique to improve protein bioavailability. Polylactic acid
(PLA) and its co-polymer with glycolic acid (i.e., PLGA) are accepted
by the regulatory authorities for parenteral administration as implants
(e.g., Zoladexs) and microparticles (e.g., Decapeptyls, Parlodel LAs
and Enantone Depots)43. The design of a novel protein nanoparticle
mainly improves protein targeting and activity in vivo. It may
(1) promote treatment outcomes with reduced adverse effects; (2) avoid
drug resistance given that redundant drug dosing and inexact targeting
can stimulate drug resistance under pathological conditions; and
(3) overcome drug resistance mechanisms with high persistent local
drug concentration32,44.
Charge-reversal polymeric carriers have emerged as more
functional protein carriers. Compared with conventional protein
carriers, they have improved properties such as increased stability,
modulated site speciﬁcity, improved blood circulation stability and
stimuli-responsive release45,46.
Akiyoshi et al.47 constructed an effective intracellular protein
delivery system from self-assembled cationic nanogels. They
investigated the interaction of proteins with self-assembled nano-
gels from cationic cholesteryl group-bearing pullulans (CHPNH2).
The cationic nanogels strongly interacted with bovine serum
albumin (BSA) which formed monodispersed nanoparticles
(o50 nm). It was found that the complex internalized into HeLa
cells effectively. Kissel and coworkers48 developed negatively
charged nano-carriers consisting of polymer blends of PLGA and
poly (styrene-co-4-styrene-sulfonate) (PSSS) to release the posi-
tively charged protein (e.g., lysozyme). This nanoparticle had a
high density of negative charge resulting in improvement of theloading capacity of proteins. Raichur et al.49 produced a stable
hollow microcapsules composed of sodium carboxymethyl cellu-
lose (CMC) and PAH using layer-by-layer techniques to absorb
polyelectrolytes onto CaCO3 microparticles. A positively charged
protein bovine serum albumin (BSA) was spontaneously loaded
below its isoelectric point into hollow microcapsules. In the acidic
pH range a ﬂuorescent probe, FITC-dextran, could be loaded,
indicating that the shell was permeable. As the pH was increased
the permeability decreased. No FITC-dextran was encapsulated
when the pH was above 7.0, indicating that the capsule walls were
impermeable. At acidic pH, the amino groups of PAH were
protonated leading to a local excess of positive charges. These
charges repulsed electrostatically resulting in transition from a
continuous to a nanoporous morphology of walls of microcap-
sules. When the pH was increased, the charge of the microcapsule
wall reversed, reducing the degree of electrostatic repulsion and
leading to compaction of the layers and closing of the pores50.5. Conclusions
The design of a drug delivery system often uses a speciﬁc ligand
for a tumor target. However, less than 5% of the dosage of an
intravenous injection is able to reach the tumor site. Smart
nanocarriers sensitive to exogenous or endogenous stimuli repre-
sent an alternative targeted drug delivery method. A wide range of
stimuli is able to trigger drug release at the desired place and time,
and the diversity of responsive materials has been assembled in
different architectures, allowing great ﬂexibility in the design of
stimuli-responsive systems on-demand.
Charge-reversal delivery strategies are designed to be sensitive
to speciﬁc stimuli, such as a lowered interstitial pH, a higher
glutathione concentration, or an increased level of certain enzymes
such as MMP. At the cellular level, pH sensitivity can either
trigger the release of the transported drug into late endosomes or
lysosomes, or promote the escape of the nanocarriers from the
lysosomes to the cell cytoplasm. At the tissue level, one can take
advantage of speciﬁc microenvironmental changes associated with
neoplastic diseases (the treatment of which is the focus of most
research efforts on stimuli-responsive nanocarriers) as well as
pathological situations, such as ischemia, inﬂammatory diseases or
infections. The ability to switch the surface charge allows one to
avoid the unspeciﬁc absorption and enhance the tumor target
delivery.
As discussed in this review, considerable progress in materials
chemistry and drug delivery has led to the design of charge-
reversal concepts using well-engineered nanosystems. The focus
should now shift towards clinically acceptable systems that are
more sensitive to discrete variations in speciﬁc stimuli. We believe
that charge-reversal drug delivery strategies for targeting tumor
treatment will provide promising avenues to treat cancers in the
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